| GENOMIC MALPRACTICE: AN EMERGING TIDE OR GENTLE RIPPLE? |
5 |
| Implementing a Public Health Perspective in FDA Drug Regulation |
3 |
| Should FDA Try to Move Smokers to E-Cigarettes and Other Less-Harmful Tobacco Products and, If So, How? |
3 |
| The Meat of the Matter: Regulating a Laboratory-Grown Alternative |
2 |
| Conflict Over Cell-Based Meat: Who Should Coordinate Agencies in US Biotechnology Regulation? |
2 |
| Step Therapy: Legal, Ethical, and Policy Implications of a Cost-Cutting Measure |
2 |
| Recommendations for Regulating Software-Based Medical Treatments: Learning from Therapies for Psychiatric Conditions |
1 |
| When Markets Fail: Patents and Infectious Disease Products |
1 |
| Alternative Organic: Legal Issues in Marketing Uncertified Organic Products |
1 |
| Natural Food Claims: Industry Practices, Consumer Expectations, and Class Action Lawsuits |
1 |
| Cannabis for Medical Use: FDA and DEA Regulation in the Hall of Mirrors |
1 |
| What Is Appropriate for the Protection of the Public Health Under the US Tobacco Control Act? |
1 |
| Toward a Global Solution on Vaccine Liability and Compensation |
1 |
| Blurred Lines: The Collapse of the Research/Clinical Care Divide and the Need for Context-Based Research Categories in the Revised Common Rule |
1 |
| The 505(b)(2) Drug Approval Pathway |
1 |
| Ruling by Repute: Agency Reputation on Judicial Affirmance of Agency Action |
0 |
| Have a (Non-Energy) Drink on Me-Modifying the Laws Regarding Energy Drinks in Australia |
0 |
| Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference |
0 |
| The Fountain of Youth Revisited: Regulatory Challenges and Pathways for Healthspan Promoting Interventions |
0 |
| The Phenomenon of Financial Toxicity: Healthcare's Insatiable Disease |
0 |
| Left to Their Own Devices: How the Dangers of Power Morcellators Went Undetected by FDA for Two Decades |
0 |
| The Emergence of ASEAN Regional Food Safety Governance: Structure, Substance, and Context |
0 |
| LEFT TO OUR OWN DEVICES, WHAT DID WE GET WRONG? THE MEDICAL DEVICE AMENDMENTS OF 1976 AS SEEN FROM THE INSIDER'S VIEW |
0 |
| Good Public Health Policy, Better Public Health Law: Blood Donation, Individual Risk Assessments, & Lifting the Deferral for Men Who Have Sex with Men |
0 |
| Changing Our Minds: Reforming the FDA Medical Device Reclassification Process |
0 |
| Is the Incorporation of the United States Pharmacopeia into the Food, Drug, and Cosmetic Act an Unconstitutional Delegation of Legislative Power? |
0 |
| Taxing Sugar-Sweetened Beverages to Combat the Costs of Obesity: City-Level Taxes and How the Federal Government Should Complement Them |
0 |
| The Regulation of Private Standards in the World Trade Organization |
0 |
| Obsolete to Useful to Obsolete Once Again: A History of Section 507 of the Food, Drug, and Cosmetic Act |
0 |
| Buying and Selling Prioritized Regulatory Review: The Market for Priority Review Vouchers as Quasi-Intellectual Property |
0 |
| The Evolving Regulatory Landscape for Clinical Trials in India |
0 |
| How Might Manufacturers of E-Cigarettes Get New Product and MRTP Orders from FDA More Quickly and Easily? |
0 |
| No Longer Business as Usual: FDA Exceptionalism, Commercial Speech, and the First Amendment |
0 |
| Agribusiness and Antibiotics: A Market-Based Solution |
0 |
| Off-Label Communications: The Prodigal Returns |
0 |
| Food Fraud and the Food, Drug, and Cosmetic Act: Bridging a Disconnect |
0 |
| Life, Liberty, [and the Pursuit of Happiness]: Medical Marijuana Regulation in Historical Context |
0 |
| Cannabis-Derived Botanical Drugs: A Viable Regulatory Pathway for Marketing Medical Edibles? |
0 |
| How FDA Could Use Its Existing Authorities to Make State Legalization of Cannabis More Safe and Effective |
0 |
| Comparing Dietary Supplement Regulations in the US and Abroad |
0 |
| Blockchainizing Food Law: Promises and Perils of Incorporating Distributed Ledger Technologies to Food Safety, Traceability, and Sustainability Governance |
0 |
| Does Attorney Advertising Stimulate Adverse Event Reporting? |
0 |
